Global pharma has treated China as a secondary market for rare disease drugs for a simple reason: th...

You have probably never heard of CHO cells unless you work in biologics or global drug manufacturing...

Over the past two decades, China’s life sciences system has undergone a structural transformation th...

How to exit China without upsetting existing customers or losing valuable revenues

A guide to the most common models software companies use to enter China In the rapidly evolving glob...